RxDoctor Payments Data

David Reese, PA

Medical · Lynchburg, VANPI 1902192248

Payments from drug & device makers

$1,362in general payments, 2019–2025

Across 84 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$568
  • Pfizer$242
  • AbbVie$92
  • Lilly USA, LLC$78
  • AstraZeneca$58
  • Abbott$41
  • plus $284 from 15 others

What the payments were for

  • Food & beverage$1,31797%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,362 in reported general payments places this provider in the 65th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$136,561
Medicare patients
374
Services billed
4,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$47,772
OzempicSemaglutide28$44,656
JanuviaSitagliptin Phosphate29$35,432
TrulicityDulaglutide22$30,539
FarxigaDapagliflozin Propanediol20$24,034
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,981
JardianceEmpagliflozin13$18,856
XareltoRivaroxaban20$18,480
LinzessLinaclotide11$7,895
TradjentaLinagliptin12$6,340
SymbicortBudesonide/Formoterol Fumarate11$5,908
Breo ElliptaFluticasone/Vilanterol14$5,458
VascepaIcosapent Ethyl13$5,227
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$2,973
Omeprazole214$2,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$242$47,77242 claims
Novo NordiskOzempic$568$44,65628 claims
MerckJanuvia$20$35,43229 claims
Lilly USA, LLCTrulicity$78$30,53922 claims
AstraZenecaFarxiga, Symbicort$58$29,94131 claims
GSKTrelegy Ellipta, Breo Ellipta$11$28,43838 claims
Boehringer IngelheimJardiance, Tradjenta$15$25,19625 claims
AbbVieLinzess, Synthroid$92$8,90331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 632 medical providers in Virginia.

Other medical in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →